Randomized, double-blind, parallel-group, placebo-controlled,ezetimibe-calibrated, multicenter study evaluating the safety and efficacy of 4 doses and 2 dose-regimens of AVE5530 (4 wks) in patients with mild to moderate hypercholesterolemia
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2011
At a glance
- Drugs Canosimibe; Ezetimibe
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 15 Dec 2008 Ezetimibe identified as an additional treatment arm as reported by ClinicalTrials.gov.
- 15 Dec 2008 Actual patient number (206) added as reported by ClinicalTrials.gov.